These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26587050)

  • 1. Refining the approach to vaccines against influenza A viruses with pandemic potential.
    Czako R; Subbarao K
    Future Virol; 2015; 10(9):1033-1047. PubMed ID: 26587050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost.
    Levine MZ; Holiday C; Jefferson S; Gross FL; Liu F; Li S; Friel D; Boutet P; Innis BL; Mallett CP; Tumpey TM; Stevens J; Katz JM
    NPJ Vaccines; 2019; 4():22. PubMed ID: 31149353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines.
    O'Neill E; Donis RO
    Curr Top Microbiol Immunol; 2009; 333():83-108. PubMed ID: 19768401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emulsion-based adjuvants for influenza vaccines.
    Vogel FR; Caillet C; Kusters IC; Haensler J
    Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and progress of prepandemic and pandemic influenza vaccine development.
    Leroux-Roels I; Leroux-Roels G
    Expert Rev Vaccines; 2009 Apr; 8(4):401-23. PubMed ID: 19348557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines for seasonal and pandemic influenza.
    Nichol KL; Treanor JJ
    J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
    Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.
    Luke CJ; Subbarao K
    Expert Rev Vaccines; 2014 Jul; 13(7):873-83. PubMed ID: 24855993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging influenza viruses and the prospect of a universal influenza virus vaccine.
    Krammer F
    Biotechnol J; 2015 May; 10(5):690-701. PubMed ID: 25728134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine approaches conferring cross-protection against influenza viruses.
    Vemula SV; Sayedahmed EE; Sambhara S; Mittal SK
    Expert Rev Vaccines; 2017 Nov; 16(11):1141-1154. PubMed ID: 28925296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study.
    Nachbagauer R; Krammer F; Albrecht RA
    Vaccines (Basel); 2018 Jul; 6(3):. PubMed ID: 30044403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.
    Rudenko L; Yeolekar L; Kiseleva I; Isakova-Sivak I
    Vaccine; 2016 Oct; 34(45):5436-5441. PubMed ID: 27593158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for the rapid deployment of vaccines against H7N9 influenza.
    Chua BY; Brown LE; Jackson DC
    Expert Rev Vaccines; 2014 Nov; 13(11):1327-37. PubMed ID: 25017993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].
    Loulergue P; Launay O
    Med Sci (Paris); 2009; 25(8-9):719-25. PubMed ID: 19765386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for licensure of influenza vaccines with pandemic and prepandemic indications.
    Baylor NW; Houn F
    Curr Top Microbiol Immunol; 2009; 333():453-70. PubMed ID: 19768419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza.
    Stamboulian D; Bonvehí PE; Nacinovich FM; Cox N
    Infect Dis Clin North Am; 2000 Mar; 14(1):141-66. PubMed ID: 10738677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.